Using a low-dose contraceptive in women 35 years of age and over: 20 μg estradiol/100 μg levonorgestrel

Bruce R. Carr, Anthony DelConte

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The efficacy, safety, and cycle control of a low-dose oral contraceptive (OC) containing 20 μg ethinyl estradiol (EE) and 100 μg levonorgestrel (LNG) has been demonstrated in a large trial with 1708 women (≥15 years old with regular menstrual cycles). The objective of this study was to analyze the same parameters in 218 of the 1708 women who were 35 years of age and older. Women were administered the 28-day, combination OC (20 μg EE/100 μg LNG; 21 days active medication/7 days placebo) for up to 3 years. During 3859 cycles evaluated for efficacy, one pregnancy occurred (Pearl index 0.34). The most common adverse events cited as reasons for discontinuation were hypertension (3% of subjects), headache (2%), and metrorrhagia (2%). One subject withdrew as a result of a serious adverse event. Breakthrough bleeding, spotting, and bleeding and spotting occurred in 2.9%, 11.0%, and 6.8%, respectively, of the 3739 cycles evaluated for cycle control. This low-dose, monophasic regimen of 20 μg EE/100 μg LNG is an effective, safe, and tolerable contraceptive and provides good cycle control for women 35 years of age and older.

Original languageEnglish (US)
Pages (from-to)397-402
Number of pages6
JournalContraception
Volume65
Issue number6
DOIs
StatePublished - 2002

Fingerprint

Levonorgestrel
Metrorrhagia
Contraceptive Agents
Ethinyl Estradiol
Estradiol
Oral Contraceptives
Menstrual Cycle
Headache
Placebos
Hemorrhage
Hypertension
Safety
Pregnancy

Keywords

  • Ethinyl estradiol
  • Levonorgestrel
  • Low-dose oral contraceptive
  • Perimenopause

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Using a low-dose contraceptive in women 35 years of age and over : 20 μg estradiol/100 μg levonorgestrel. / Carr, Bruce R.; DelConte, Anthony.

In: Contraception, Vol. 65, No. 6, 2002, p. 397-402.

Research output: Contribution to journalArticle

@article{01764c2fec8b410386668fbc7f59f4d2,
title = "Using a low-dose contraceptive in women 35 years of age and over: 20 μg estradiol/100 μg levonorgestrel",
abstract = "The efficacy, safety, and cycle control of a low-dose oral contraceptive (OC) containing 20 μg ethinyl estradiol (EE) and 100 μg levonorgestrel (LNG) has been demonstrated in a large trial with 1708 women (≥15 years old with regular menstrual cycles). The objective of this study was to analyze the same parameters in 218 of the 1708 women who were 35 years of age and older. Women were administered the 28-day, combination OC (20 μg EE/100 μg LNG; 21 days active medication/7 days placebo) for up to 3 years. During 3859 cycles evaluated for efficacy, one pregnancy occurred (Pearl index 0.34). The most common adverse events cited as reasons for discontinuation were hypertension (3{\%} of subjects), headache (2{\%}), and metrorrhagia (2{\%}). One subject withdrew as a result of a serious adverse event. Breakthrough bleeding, spotting, and bleeding and spotting occurred in 2.9{\%}, 11.0{\%}, and 6.8{\%}, respectively, of the 3739 cycles evaluated for cycle control. This low-dose, monophasic regimen of 20 μg EE/100 μg LNG is an effective, safe, and tolerable contraceptive and provides good cycle control for women 35 years of age and older.",
keywords = "Ethinyl estradiol, Levonorgestrel, Low-dose oral contraceptive, Perimenopause",
author = "Carr, {Bruce R.} and Anthony DelConte",
year = "2002",
doi = "10.1016/S0010-7824(02)00292-5",
language = "English (US)",
volume = "65",
pages = "397--402",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Using a low-dose contraceptive in women 35 years of age and over

T2 - 20 μg estradiol/100 μg levonorgestrel

AU - Carr, Bruce R.

AU - DelConte, Anthony

PY - 2002

Y1 - 2002

N2 - The efficacy, safety, and cycle control of a low-dose oral contraceptive (OC) containing 20 μg ethinyl estradiol (EE) and 100 μg levonorgestrel (LNG) has been demonstrated in a large trial with 1708 women (≥15 years old with regular menstrual cycles). The objective of this study was to analyze the same parameters in 218 of the 1708 women who were 35 years of age and older. Women were administered the 28-day, combination OC (20 μg EE/100 μg LNG; 21 days active medication/7 days placebo) for up to 3 years. During 3859 cycles evaluated for efficacy, one pregnancy occurred (Pearl index 0.34). The most common adverse events cited as reasons for discontinuation were hypertension (3% of subjects), headache (2%), and metrorrhagia (2%). One subject withdrew as a result of a serious adverse event. Breakthrough bleeding, spotting, and bleeding and spotting occurred in 2.9%, 11.0%, and 6.8%, respectively, of the 3739 cycles evaluated for cycle control. This low-dose, monophasic regimen of 20 μg EE/100 μg LNG is an effective, safe, and tolerable contraceptive and provides good cycle control for women 35 years of age and older.

AB - The efficacy, safety, and cycle control of a low-dose oral contraceptive (OC) containing 20 μg ethinyl estradiol (EE) and 100 μg levonorgestrel (LNG) has been demonstrated in a large trial with 1708 women (≥15 years old with regular menstrual cycles). The objective of this study was to analyze the same parameters in 218 of the 1708 women who were 35 years of age and older. Women were administered the 28-day, combination OC (20 μg EE/100 μg LNG; 21 days active medication/7 days placebo) for up to 3 years. During 3859 cycles evaluated for efficacy, one pregnancy occurred (Pearl index 0.34). The most common adverse events cited as reasons for discontinuation were hypertension (3% of subjects), headache (2%), and metrorrhagia (2%). One subject withdrew as a result of a serious adverse event. Breakthrough bleeding, spotting, and bleeding and spotting occurred in 2.9%, 11.0%, and 6.8%, respectively, of the 3739 cycles evaluated for cycle control. This low-dose, monophasic regimen of 20 μg EE/100 μg LNG is an effective, safe, and tolerable contraceptive and provides good cycle control for women 35 years of age and older.

KW - Ethinyl estradiol

KW - Levonorgestrel

KW - Low-dose oral contraceptive

KW - Perimenopause

UR - http://www.scopus.com/inward/record.url?scp=0036597741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036597741&partnerID=8YFLogxK

U2 - 10.1016/S0010-7824(02)00292-5

DO - 10.1016/S0010-7824(02)00292-5

M3 - Article

C2 - 12127636

AN - SCOPUS:0036597741

VL - 65

SP - 397

EP - 402

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 6

ER -